Cargando…

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study

BACKGROUND: Chronic hepatitis C is a major public health issue, but there is a gap in the literature regarding the effectiveness and safety of direct-acting antiviral agents in the Brazilian population. The main aim of this study was to describe the effectiveness of boceprevir and telaprevir in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Borba, Helena HL, Wiens, Astrid, Steimbach, Laiza M, Tonin, Fernanda S, Pedroso, Maria LA, Ivantes, Cláudia AP, Fernandez-Llimos, Fernando, Pontarolo, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237588/
https://www.ncbi.nlm.nih.gov/pubmed/28138248
http://dx.doi.org/10.2147/TCRM.S124663
_version_ 1782495555899883520
author Borba, Helena HL
Wiens, Astrid
Steimbach, Laiza M
Tonin, Fernanda S
Pedroso, Maria LA
Ivantes, Cláudia AP
Fernandez-Llimos, Fernando
Pontarolo, Roberto
author_facet Borba, Helena HL
Wiens, Astrid
Steimbach, Laiza M
Tonin, Fernanda S
Pedroso, Maria LA
Ivantes, Cláudia AP
Fernandez-Llimos, Fernando
Pontarolo, Roberto
author_sort Borba, Helena HL
collection PubMed
description BACKGROUND: Chronic hepatitis C is a major public health issue, but there is a gap in the literature regarding the effectiveness and safety of direct-acting antiviral agents in the Brazilian population. The main aim of this study was to describe the effectiveness of boceprevir and telaprevir in patients treated at public health care institutions in Brazil. MATERIALS AND METHODS: A prospective longitudinal and multicenter study was conducted in five centers in the State of Paraná between September 2014 and June 2016. Data regarding effectiveness and safety were collected from medical records of patients treated with boceprevir or telaprevir. The effectiveness outcome comprised the rapid virological response (RVR). Multivariate analysis was performed to verify the influence of independent variables (ie, age, gender, baseline viral load) on RVR achievement. RESULTS: Data were collected from 117 patients with chronic hepatitis C virus (HCV) genotype 1 infection. Fifteen patients received treatment with boceprevir and 102 received telaprevir. The mean age was 51.6 years, 64.1% were male, 44.4% were infected with HCV subtype 1a, 62.4% had a high baseline viral load (≥800,000 IU/mL) and 33% were cirrhotic. Furthermore, 79.5% of patients achieved RVR (26.7% in the boceprevir group and 87.3% in the telaprevir group). Multivariate analysis demonstrated that the type of protease inhibitor (boceprevir or telaprevir) and the baseline viral load had an influence on the RVR rate (odds ratio [OR] =0.011; 95% confidence interval [CI]: 0.001–0.119; P<0.001/OR =13.004; 95% CI: 1.522–111.115; P=0.019, respectively). CONCLUSION: In this longitudinal multicenter cohort study conducted from the Brazilian perspective, differences were found in the RVR rates, favoring telaprevir over boceprevir for genotype 1 HCV-infected patients. In addition, the baseline viral load was associated with RVR achievement in both evaluated groups. As RVR is also reported in the literature as a predictor of the sustained virological response (SVR), further analyses of RVR as predictor of SVR outcomes should be further evaluated in Brazil.
format Online
Article
Text
id pubmed-5237588
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-52375882017-01-30 Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study Borba, Helena HL Wiens, Astrid Steimbach, Laiza M Tonin, Fernanda S Pedroso, Maria LA Ivantes, Cláudia AP Fernandez-Llimos, Fernando Pontarolo, Roberto Ther Clin Risk Manag Original Research BACKGROUND: Chronic hepatitis C is a major public health issue, but there is a gap in the literature regarding the effectiveness and safety of direct-acting antiviral agents in the Brazilian population. The main aim of this study was to describe the effectiveness of boceprevir and telaprevir in patients treated at public health care institutions in Brazil. MATERIALS AND METHODS: A prospective longitudinal and multicenter study was conducted in five centers in the State of Paraná between September 2014 and June 2016. Data regarding effectiveness and safety were collected from medical records of patients treated with boceprevir or telaprevir. The effectiveness outcome comprised the rapid virological response (RVR). Multivariate analysis was performed to verify the influence of independent variables (ie, age, gender, baseline viral load) on RVR achievement. RESULTS: Data were collected from 117 patients with chronic hepatitis C virus (HCV) genotype 1 infection. Fifteen patients received treatment with boceprevir and 102 received telaprevir. The mean age was 51.6 years, 64.1% were male, 44.4% were infected with HCV subtype 1a, 62.4% had a high baseline viral load (≥800,000 IU/mL) and 33% were cirrhotic. Furthermore, 79.5% of patients achieved RVR (26.7% in the boceprevir group and 87.3% in the telaprevir group). Multivariate analysis demonstrated that the type of protease inhibitor (boceprevir or telaprevir) and the baseline viral load had an influence on the RVR rate (odds ratio [OR] =0.011; 95% confidence interval [CI]: 0.001–0.119; P<0.001/OR =13.004; 95% CI: 1.522–111.115; P=0.019, respectively). CONCLUSION: In this longitudinal multicenter cohort study conducted from the Brazilian perspective, differences were found in the RVR rates, favoring telaprevir over boceprevir for genotype 1 HCV-infected patients. In addition, the baseline viral load was associated with RVR achievement in both evaluated groups. As RVR is also reported in the literature as a predictor of the sustained virological response (SVR), further analyses of RVR as predictor of SVR outcomes should be further evaluated in Brazil. Dove Medical Press 2017-01-10 /pmc/articles/PMC5237588/ /pubmed/28138248 http://dx.doi.org/10.2147/TCRM.S124663 Text en © 2017 Borba et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Borba, Helena HL
Wiens, Astrid
Steimbach, Laiza M
Tonin, Fernanda S
Pedroso, Maria LA
Ivantes, Cláudia AP
Fernandez-Llimos, Fernando
Pontarolo, Roberto
Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
title Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
title_full Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
title_fullStr Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
title_full_unstemmed Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
title_short Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
title_sort rapid virological response of telaprevir and boceprevir in a brazilian cohort of hcv genotype 1 patients: a multicenter longitudinal study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237588/
https://www.ncbi.nlm.nih.gov/pubmed/28138248
http://dx.doi.org/10.2147/TCRM.S124663
work_keys_str_mv AT borbahelenahl rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy
AT wiensastrid rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy
AT steimbachlaizam rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy
AT toninfernandas rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy
AT pedrosomariala rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy
AT ivantesclaudiaap rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy
AT fernandezllimosfernando rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy
AT pontaroloroberto rapidvirologicalresponseoftelaprevirandboceprevirinabraziliancohortofhcvgenotype1patientsamulticenterlongitudinalstudy